drugset / Trial / NCT00030641

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

NCT00030641

RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of docetaxel by making the tumor cells more sensitive to the drug. It is not yet known if docetaxel is more effective with or without oblimersen in treating non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of docetaxel with or without oblimersen in treating patients who have relapsed or refractory non-small cell lung cancer that has been previously treated.

Timeline

Start
2001-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject oblimersen sodium Antisense oligonucleotide Intravenous

Indications